Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butein SCHEMBL29724857 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL243647 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL30383523 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL505501 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL139243 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL25202104 | 1.00 | KMT2A (1.00) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL25200377 | 0.98 | KMT2A (0.97) | KMT2AMEN1NFKB1NFKB2RELA | |
| SCHEMBL25208375 | 0.90 | MEN1 (0.96) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL25209583 | 0.89 | KMT2A (0.80) | KMT2AMEN1NFKB1NFKB2RELA | |
| Butein SCHEMBL1706409 | 0.89 | KMT2A (0.80) | KMT2AMEN1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815893-B2 | Anti-VEGF antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2894167-B1 | Anti-VEGF Antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2925778-B1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2493929-B1 | ANTI-EGFR ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2513148-B1 | ANTI-HER2 ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20150299307-A1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC. | 2015-10-22 | — | — | US | disclosed |
| EP-2925778-A1 | ANTI-VEGF ANTIBODIES AND THEIR USES | AbbVie Biotherapeutics Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2894167-A1 | Anti-VEGF Antibodies and their uses | AbbVie Biotherapeutics Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-9079953-B2 | Anti-VEGF antibodies and their uses | ABBVIE BIOTHERAPEUTICS INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2443150-B1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | disclosed |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2376087-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | Santaris Pharma A/S (DK) | 2011-10-19 | — | — | EP | disclosed |
| US-20110177095-A1 | ANTI-HER2 ANTIBODIES AND THEIR USES | Abbott Biotherapeutics Corporation (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084496-A1 | ANTI-HER2 ANTIBODIES AND THEIR USES | ABBOTT BIOTHERAPEUTICS CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110117110-A1 | ANTI-EGFR ANTIBODIES AND THEIR USES | FACET BIOTECH CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011059762-A1 | ANTI-EGFR ANTIBODIES AND THEIR USES | ABBOTT BIOTHERAPEUTICS CORP. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010148223-A2 | ANTI-VEGF ANTIBODIES AND THEIR USES | FACET BIOTECH CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100322931-A1 | ANTI-VEGF ANTIBODIES AND THEIR USES | ABBVIE BIOTHERAPEUTICS INC. | 2010-12-23 | — | — | US | disclosed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | KMT2A 1292/4885MEN1 2801/4885NFKB1 4255/4885 |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ERBB3, ERBB2, EGFR | KMT2A 2276/4885MEN1 2296/4885NFKB1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.